Company intelligence
VitroScan
Predicting treatment outcome
About VitroScan
VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. We develop certified predictive ex vivo 3D tumor testing services for reliable treatment response prediction for the clinic and to improve patient stratification for clinical trials. Our proprietary technology provides highly reproducible drug testing in the native tumor microenvironment (TME). VitroScan’s clinical trial program is performed in collaboration with expert clinicians from leading oncology centers. In these trials patient specific ex vivo tumor sensitivity to chemo-, targeted, or immunotherapy is correlated to clinical outcomes. We are dedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients. Explore our website to learn more www.vitroscan.com
Verified activity
Signals from VitroScan
6 published signals
Research & Knowledge
VitroScan published an article in the second issue of the Translational Research journal exploring tumor heterogeneity and patient-derived ex vivo models.
Reported by VitroScan
Presence & Recognition
VitroScan was featured in the NOS Journal, Radio1, and NOS.nl in an item discussing the national investment fund and the financing gate for innovative Dutch businesses.
Reported by VitroScan
Presence & Recognition
VitroScan will be featured in news items on NOS national radio and television
Reported by VitroScan